All About Troriluzole

We have received lots of questions from our community about Troriluzole, an investigational therapy for SCA. In this session, we went over some of the most common questions we have received about Troriluzole. Then there was an open Q&A session for attendees to ask their own questions.

Troriluzole is an investigational therapy that is under evaluation and not approved by the FDA. Anyone considering participating in a clinical trial or trying a new medication should discuss the matter with their physician. The National Ataxia Foundation does not endorse or recommend particular studies or treatment options

About the Speaker-
Title: Susan Perlman, MD
Institution: UCLA

Bio: Dr. Perlman is a graduate of Cornell University and the State University of New York at Stony Brook School of Medicine. She did an internship in medicine, her residency in neurology, and a two-year fellowship in Friedreich’s Ataxia at UCLA Medical Center. Dr. Perlman is currently a Clinical Professor of Neurology and Director of the Ataxia Center at the UCLA Medical Center in Los Angeles, CA. She has been head of the Ataxia Center at UCLA since 1983. She has worked in Ataxia diagnosis for over 30 years and has networked with other “Ataxologists” across the country and around the world, trying to build better collaboration in the development to treatments and ultimately cures. She helped develop the National Ataxia Database for clinical research. She is participating in 2 natural history studies (for dominant Ataxia and Friedreich’s Ataxia) and has participated in 7 clinical drug trials. Dr. Perlman would like to expand the work being done in non-genetic Ataxia as well. Dr. Perlman authored Evaluation and Management of Ataxic Disorders: An Overview for Physicians which has become a valuable resource for NAF. She serves on NAF’s Medical Research Advisory Board and is an ex-officio member of NAF’s Board of Directors.